|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.55 USD | +2.55% |
|
+21.91% | +24.64% |
| 01-11 | Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises | RE |
| 01-07 | UBS Initiates Beam Therapeutics at Neutral With $28 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.32B | - | - | - | ||
| 49.9B | |||||
| 41.02B | |||||
| 36.96B | |||||
| 31.91B | |||||
| 22.65B | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition